
Commentary|Articles|December 10, 2014
Pembrolizumab for TNBC
Author(s)Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Advertisement
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
- Inhibiting the PD-1 pathway showed activity in advanced TNBC in a previous phase I study.
- In this study, a heavily pretreated population of patients with TNBC tolerated pembrolizumab well. Durable responses were observed.
- There remains a need for breast cancer doctors to understand how to manage toxicities associated with immunotherapies.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































